Stress-Reducing Interventions in HIV+ Patients: Pilot

Pilot Intervention for PTSD, Nonadherence, and HIV Risk

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00599599

Acronym

PEACH

Enrollment

Registered

2008-01-24

Start date

2005-04-30

Completion date

2010-02-28

Last updated

2009-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections, Stress Disorders, Post-Traumatic

Keywords

Prolonged Exposure Therapy, Adherence to HIV Medications, Complementary Therapies

Brief summary

The primary aim of this project is to examine the efficacy of prolonged exposure (PE) therapy at reducing HIV-related PTSD symptoms, increasing adherence to antiretroviral medication regimens, and increasing health-related quality of life (QOL) in HIV+ patients.

Detailed description

HIV+ patients will be randomized to receive either PE therapy (up to 18 possible sessions) or weekly symptom monitoring (described below) and will complete measures of PTSD, adherence, and QOL pre- and post-intervention and at 3- and 6-month follow-up assessments. Secondary analyses will examine the impact of the intervention on disorders commonly comorbid with PTSD (i.e., anxiety, mood, and substance abuse/dependence disorders).

Interventions

BEHAVIORALProlonged Exposure Therapy

Participants will meet with a therapist twice a week for 5 weeks to complete the therapy. If the therapist and participant feel more sessions are needed, an additional 8 sessions will be provided.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Must be HIV+ * Must meet PTSD diagnostic criteria * Must be taking HIV medications * Must be able to read and write in English

Exclusion criteria

* Current or previous diagnosis of schizophrenia, any current diagnosis with psychotic features, or current suicidal ideation * Being in a current abusive relationship or ongoing intimate relationship with one's assailant * Mental retardation

Design outcomes

Primary

Measure	Time frame
PTSD symptoms	pre- & post-intervention, 3-month post, & 6-month post

Secondary

Measure	Time frame
Adherence to HIV medications	pre- & post-intervention, 3-month post, & 6-month post
Health-related Quality of Life	pre- & post-intervention, 3-month post, & 6-month post

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026